South Korean next-generation sequencing-based diagnostic firm NGeneBio said on Friday that it has entered a collaboration agreement with Chinese sequencing platform company MGI Tech to expand the commercial access of NGeneBio's cancer testing products.

On June 15, 2023, the inaugural meeting of Institute of Bioinformatics of Shanghai Academy of Experimental Medicine (hereinafter referred to as "Institute of Bioinformatics") and Gene Sequencing Bioinformatics Research Summit Forum was held in Intercontinental Hotel in Jing'an, Shanghai. Ltd.

Pfizer and Thermo Fisher Scientific Inc. announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia.

Stockholm, Sweden-based Devyser Diagnostics on Monday announced that it has inked a collaboration and distribution agreement that gives Thermo Fisher Scientific the exclusive rights to commercialize its post-transplant portfolio of next-generation sequencing (NGS) products in North America and Europe.

Pillar Biosciences said on Thursday that it has acquired a nonexclusive license to high-throughput screening-related intellectual property from Dutch ag-bio firm KeyGene.

Recently, WillingMed Technology(Beijing) Co., Ltd. announced the completion of a CNY hundreds of millions Series B financing round.

Which segmentations will have a broader development prospect in the Chinese IVD field?

Liquid handling instrumentation firm Integra Biosciences said that it has acquired Miroculus, a sample prep automation company that has been developing microfluidics-based platforms for next-generation sequencing.

On March 10, 2023, Shenzhen MGI Tech Co.,Ltd. and Yeasen Biotechnology (Shanghai) Co., Ltd. officially reached a strategic cooperation to promote the localization of high-throughput sequencing (NGS) reagents and instruments in China.

QIAGEN N.V. announced the launch of the new QIAseq Platform Partnership program and the first partnership with medical data-analysis provider SOPHiA GENETICSTM that will bring together its QIAseq reagent technology for next-generation sequencing with the SOPHiA DDMTM digital analytics platform.